#5 - Medtronic (NYSE:MDT)
Medtronic (NYSE: MDT) - There is a lot of uncertainty in the healthcare sector as the debate about the future of the Affordable Care Act continues. There is less uncertainty about the continued need for the medical devices and services that are a part of healthcare in general and an aging population in particular. That's where Medtronic comes in. The medical technology company recently had a stellar earnings report on both the top and bottom line that saw its stock rise 5.7% to reach a record high of $95.17. This recent jump means the stock has risen by 18% in 2018. Fueling the rise were the company's diabetes and pain therapy devices as well as their cardiac and vascular group which includes sales of transcatheter aortic heart valve replacements (TAVR). Worldwide revenue from these sales outgrew the market by nearly 20 percent. And Medtronic has the highest market share in Western and Eastern Europe. In terms of fundamentals, the stock is currently trading at just 16x fiscal 2018 guidance of approximately $5, and it issued a respectable 2.3% dividend yield. It has strong forward guidance.
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Read More - Current Price
- $86.21
- Consensus Rating
- Hold
- Ratings Breakdown
- 7 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $95.00 (10.2% Upside)
